BioCentury
ARTICLE | Company News

Japan BCG, Dainippon Sumitomo, Aeras, National Institute of Biomedical Innovation deal

February 3, 2014 8:00 AM UTC

Create Vaccine Co. Ltd. - a JV between Dainippon and Japan BCG - and the institute announced they signed a formal partnership with the foundation to jointly develop mucosal tuberculosis vaccines based on the institute's human parainfluenza type-2 vector technology. The parties announced a memorandum for the deal in November. Under the deal, the institute will be responsible for discovery and preclinical development, the foundation and Create Vaccine will be responsible for clinical development, and Create Vaccine will be responsible for manufacturing and marketing the vaccines. The work will be funded with a ¥70 million ($686,000) grant from the Global Health Innovative Technology Fund (GHIT). The partners are not disclosing which party will own the rights to products developed under the deal, according to Dainippon (see BioCentury, Nov. 11, 2013). ...